Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Study sponsor: TG Therapeutics, Inc. · TGTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-02-15Actual
Enrollment · participants21Actual
Source updated2023-06-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.